Screener
Theravance Biopharma TBPH Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease assets | 23,001 | 24,371 |
| Restricted cash | 836 | 836 |
| Other assets | 25,303 | 24,880 |
| Total assets | $472,313 | $485,570 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,100 | $2,568 |
| Accrued personnel-related expenses | 8,730 | 12,592 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's total assets?
- Theravance Biopharma (TBPH) reported total assets of $472.31M in Q1 2026.
- How has Theravance Biopharma's total assets changed year-over-year?
- Theravance Biopharma's total assets increased by 37.5% year-over-year, from $343.58M to $472.31M.
- What is the long-term trend for Theravance Biopharma's total assets?
- Over 5 years (2020 to 2025), Theravance Biopharma's total assets has grown at a 0.7% compound annual growth rate (CAGR), from $469.06M to $485.57M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about Theravance Biopharma's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude